...
首页> 外文期刊>Glia >Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway
【24h】

Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway

机译:神经损伤后,神经调节蛋白-1通过MEK / ERK途径驱动小胶质细胞增殖和神经性疼痛

获取原文
获取原文并翻译 | 示例

摘要

Following peripheral nerve injury microglia accumulate within the spinal cord and adopt a proinflammatory phenotype a process which contributes to the development of neuropathic pain. We have recently shown that neuregulin-1, a growth factor released following nerve injury, activates erbB 2, 3, and 4 receptors on microglia and stimulates proliferation, survival and chemotaxis of these cells. Here we studied the intracellular signaling pathways downstream of neuregulin-1-erbB activation in microglial cells. We found that neuregulin-1 in vitro induced phosphorylation of ERK1/2 and Akt without activating p38MAPK. Using specific kinase inhibitors we found that the mitogenic effect of neuregulin-1 on microglia was dependant on MEK/ERK1/2 pathway, the chemotactic effect was dependant on PI3K/Akt signaling and survival was dependant on both pathways. Intrathecal treatment with neuregulin-1 was associated with microgliosis and development of mechanical and cold pain related hypersensitivity which was dependant on ERK1/2 phosphorylation in microglia. Spinal nerve ligation results in a robust microgliosis and sustained ERK1/2 phosphorylation within these cells. This pathway is downstream of neuregulin-1/erbB signaling since its blockade resulted in a significant reduction in microglial ERK1/2 phosphorylation. Inhibition of the MEK/ERK1/2 pathway resulted in decreased spinal microgliosis and in reduced mechanical and cold hypersensitivity after peripheral nerve damage. We conclude that neuregulin-1 released after nerve injury activates microglial erbB receptors which consequently stimulates the MEK/ERK1/2 pathway that drives microglial proliferation and contributes to the development of neuropathic pain.
机译:周围神经损伤后,小胶质细胞积聚在脊髓内并采用促炎表型,这一过程有助于神经性疼痛的发展。我们最近发现神经调节蛋白1是神经损伤后释放的一种生长因子,可激活小胶质细胞上的erbB 2、3和4受体,并刺激这些细胞的增殖,存活和趋化性。在这里我们研究了小胶质细胞中neuregulin-1-erbB激活下游的细胞内信号通路。我们发现neuregulin-1体外诱导ERK1 / 2和Akt的磷酸化而未激活p38MAPK。使用特定的激酶抑制剂,我们发现神经调节蛋白1对小胶质细胞的促有丝分裂作用取决于MEK / ERK1 / 2途径,趋化作用取决于PI3K / Akt信号传导,而存活率则取决于这两种途径。鞘内注射neuregulin-1与小胶质细胞增生以及与机械性疼痛和冷痛相关的超敏反应有关,超敏反应取决于小胶质细胞中ERK1 / 2磷酸化。脊髓神经结扎可导致这些细胞内发生牢固的小胶质细胞增生和持续的ERK1 / 2磷酸化。该途径位于neuregulin-1 / erbB信号传导的下游,因为它的阻断导致小胶质ERK1 / 2磷酸化的显着降低。 MEK / ERK1 / 2途径的抑制导致脊髓微胶质细胞减少和周围神经损伤后机械和冷的超敏反应减少。我们得出的结论是,神经损伤后释放的神经调节蛋白1激活了小胶质erbB受体,从而刺激了驱动小胶质细胞增殖并促进神经性疼痛发展的MEK / ERK1 / 2途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号